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Abstract 
Constitutive activation of the pro-survival transcription factor NF-B has been associated 
with resistance to both chemotherapy and radiation therapy in many human cancers, including 
prostate cancer. Our lab and others have demonstrated that the natural product parthenolide can 
inhibit NF-B activity and sensitize PC-3 prostate cancers cells to X-rays in vitro; however, 
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parthenolide has poor bioavailability in vivo and therefore has little clinical utility in this regard. 
We show here that treatment of PC-3 and DU145 human prostate cancer cells with 
dimethylaminoparthenolide (DMAPT), a parthenolide derivative with increased bioavailability, 
inhibits constitutive and radiation-induced NF-B binding activity and slows prostate cancer cell 
growth. We also show that DMAPT increases single and fractionated X-ray-induced killing of 
prostate cancer cells through inhibition of DNA double strand break repair and also that 
DMAPT-induced radiosensitization is, at least partially, dependent upon the alteration of 
intracellular thiol reduction-oxidation chemistry. Finally, we demonstrate that the treatment of 
PC-3 prostate tumor xenografts with oral DMAPT in addition to radiation therapy significantly 
decreases tumor growth and results in significantly smaller tumor volumes compared to 
xenografts treated with either DMAPT or radiation therapy alone, suggesting that DMAPT might 
have a potential clinical role as a radiosensitizing agent in the treatment of prostate cancer. 
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Introduction 
 Despite decreasing incidence over recent years, prostate cancer remains the most commonly 
diagnosed cancer in men, with the American Cancer Society projecting 186,890 new cases of 
prostate cancer in the US in 2016 (1). Moreover, the American Cancer Society estimates 26,120 
men will die of prostate cancer in 2016, making it the second leading cause of cancer death in 
men (1). Older men diagnosed with prostate cancer tend to have a relatively good prognosis, as 
they are typically either successfully treated or do not succumb to the disease prior to dying of 
other causes (2-7). However, the prognosis of younger men and African American men 
diagnosed with prostate cancer, in whom the disease is often more aggressive and has the 
potential to metastasize earlier, is typically much worse (2-7). Thus, there remains a large need 
for the development of more effective treatment methods for men with prostate cancer in 
populations that tend to have more aggressive cancers. Although radiation therapy can be a quite 
effective treatment modality for patients with prostate cancer, resistance to radiation therapy and 
resulting local failures and reoccurrences are not uncommon; this is especially true in 
populations that typically have more aggressive prostate cancers (2-7).  
 As is the case with many cancers that are resistant to radiation therapy, radiation-resistant 
prostate cancer cells often overexpress the transcription factor NF-B (8-11). Constitutive 
activation of NF-B has been implicated in resistance to both radiation therapy and 
chemotherapy in cancer cells, and has also been shown to play a role in the stimulation of tumor 
cell growth, inhibition of apoptosis, and facilitation of tumor invasion, metastasis, and 
angiogenesis (8-17). Not only is NF-B constitutively active in many human tumors, it is also 
often induced by exposure to X-rays, therefore increasing its ability to facilitate resistance to 
radiation therapy (10, 11, 17). Because of the ubiquity of the role played by NF-B in resistance 
to current cancer treatment modalities, the search for novel therapies that inhibit NF-B is of 
great interest. One such therapy that has been studied by our lab and others is related to the 
naturally-occurring compound parthenolide. 
 Parthenolide is a naturally occurring sesquiterpene lactone that is an active ingredient in the 
medicinal plant Tanacetum parthenum, commonly known as Feverfew, which has traditionally 
been used as an herbal remedy for arthritis and migraine headaches (18, 19). Parthenolide has 
been shown to inhibit NF-B activity by preventing the breakdown of IB- and IB-, both of 
which are responsible for the sequestration of NF-B to the cytoplasm (18-24). Moreover, our 
lab and others have shown that parthenolide inhibits constitutive and radiation-induced NF-B 
activity and human tumor xenograft growth, and enhances X-ray-induced tumor cell killing 
through inhibition of split-dose repair (25-28). Parthenolide has also been shown to have a 
variety of other anti-neoplastic actions including: activation of caspases and pro-apoptotic 
regulators such as BAX, induction of reactive oxygen species and apoptosis-related transcription 
factors such as GADD153, and alteration of cell cycle distributions via the cyclin-dependent 
kinase inhibitor p21
waf-1/cip1
 (18, 19, 25-31). Moreover, parthenolide-induced apoptosis has also 
shown to be significantly mediated by depletion of intracellular thiols (32). 
 Despite its anti-neoplastic properties, parthenolide unfortunately has a rather low 
bioavailability, which limits its clinical utility (33).  In one study, human volunteers were given 
up to 4 mg of Tanacetum parthenum extract orally with no detectable parthenolide in the plasma 
(<0.5ng/mL) (33). As a remedy for this problem, a derivative of parthenolide, 
dimethylaminoparthenolide (DMAPT), which has a much higher oral bioavailability than 
parthenolide, has been developed (28,34-38). In a mouse model, 100 mg/kg of oral DMAPT 
produced a maximum serum concentration of 25 M, compared to a maximum possible serum 
concentration of 0.2 M with oral parthenolide (34). 
 Like parthenolide, DMAPT, has been shown to be a potent inhibitor of NF-B. Previous 
work in our lab showed that DMAPT inhibited NF-B activity in non-small cell lung cancer 
cells and sensitized these cells to X-rays (28). There is evidence that DMAPT promotes prostate 
cancer cell death in vivo via both inhibition of NF-B activity and generation of reactive oxygen 
species (ROS) (34). Moreover, very recent work by Morel et al demonstrated the ability of 
parthenolide and DMAPT to radiosensitize prostate cancer cells in vivo in a transgenic 
adenocarcinoma of the mouse prostate (TRAMP) model while acting as a radioprotecting agent 
in normal tissue (39). While these studies give us additional insight into the ability of DMAPT to 
induce radiosensitization, there is still relatively little data on the mechanism of DMAPT-
induced radiosensitization in human prostate cancer cells. Given that the α-methylene-γ-lactone 
group of parthenolide, which is altered in DMAPT, contributes to the ability of parthenolide to 
act as a thiol alkylating agent and deplete intracellular thiols, it is reasonable to question whether 
the radiosensitizing effects of DMAPT are dependent upon its ability to react with biological 
thiols (40). Moreover, given our evidence that DMAPT-induced X-ray sensitivity of lung cancer 
occurs, at least partially, via the inhibition of split-dose repair (28), we investigated whether 
DMAPT is capable of significantly increasing the sensitivity of prostate cancer to X-rays through 
this mechanism, and thus our work here was aimed at answering these questions.  Our results 
show that treatment of PC-3 (p53 null) and DU145 (p53 mutant) human prostate cancer cells 
with DMAPT inhibits NF-B activity, cell growth, and DNA double strand break repair; and 
increases radiation-induced cell killing of single and fractionated X-ray treatments of PC-3 and 
DU145 cells in vitro, and of a single fraction of X-rays given to PC-3 tumor xenografts in vivo. 
Moreover, our results show that pre-treatment with the thiol antioxidant N-acetylcysteine (NAC), 
reduced, but did not completely eliminate the enhanced radiation-induced cell killing seen in 
cells treated with DMAPT, suggesting that DMAPT-induced radiosensitization is partially 
dependent on its ability to interact with biological thiols. 
 
Materials and Methods 
Cell lines   
 PC-3 is a p53 null, human androgen-independent prostate cancer cell line that was obtained 
from Dr. Tom Gardner, Indiana University School of Medicine (41).  DU145 is a p53 mutated, 
human hormone-insensitive prostate adenocarcinoma cell line originally isolated from a brain 
metastasis that was also obtained from Dr. Tom Gardner, Indiana University School of Medicine 
(42-44). Neither PC-3 nor DU145 express androgen receptors (AR) or prostate specific antigen 
(PSA). The cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium with L-
glutamine (Thermo Fisher Scientific, Waltham, MA), 10% FBS (Hyclone, Logan, UT), and 1% 
penicillin/streptomycin (Cellgro, Herndon VA).  Cells were cultured at 37C, 5% CO2, and 85% 
humidity. Subconfluent stock cultures plated at 6.0 x 105 cells were grown in T-75 tissue culture 
flasks 1 to 3 days prior to all experiments.  The PC-3 in vitro population doubling time and 
plating efficiency were 23 ± 5 h and 35 ± 5%, respectively.  The DU145 in vitro population 
doubling time and plating efficiency were 20.4 ± 2.2 h and 45 ± 8%, respectively.  
 
Assessment of constitutive NF-B binding activity, plating efficiency, apoptosis, cell cycle 
distribution and cell growth in PC-3 and DU145 cells  
 Dimethylaminoparthenolide (DMAPT) was synthesized by Dr. Peter Crooks and is a 
derivative of parthenolide, a sesquiterpene lactone, extracted from the Feverfew plant (28, 34-
38).  PC-3 and DU145 cells were harvested from exponentially growing stock cultures and 
plated in T-25 flasks (Corning, Corning, NY).  Twenty-four and forty-eight hours after plating, 
appropriate volumes of 36 mM DMAPT drug stock diluted in RPMI were directly added to the 
cell culture flasks so that final DMAPT concentrations were 0, 2.5, and 5 M DMAPT for PC-3 
and 0 and 4 M DMAPT for DU145 cells. Control and treated cells were harvested for NF-B 
EMSA/Gel shifts, cell counting/growth curve analysis, clonogenic potential/plating efficiency 
studies, flow cytometry based apoptosis analysis by Annexin V-phosphatidylserine analysis, 
comet assays to determine DNA double strand break repair, flow cytometry based DNA 
histogram cell cycle analysis after propidium iodide staining, and Western analyses 24 and 48 
hours after drug addition by our standard techniques (12, 26, 28, 45, 46).  Since the initial NF-B 
EMSA/Gel shifts clearly showed better inhibition of NF-kB binding at 5 M DMAPT, all other 
experiments with PC-3 were performed at 5 M DMAPT. 
 
Electrophoretic mobility shift assay (EMSA) 
 PC-3 cells were treated with 0 or 5 M of DMAPT and DU145 cells were treated with 0 or 4 
M of DMAPT at 24 and 48 hours as described above and then cell extracts were harvested by 
scraping flasks on ice for NF-B EMSA/Gel Shift analysis by our standard methods described 
previously (12, 26, 28). The NF-B oligonucleotide, 5’-AGTTGAGGGGACTTTCCCAGG-3’, 
containing the NF-B DNA binding consensus sequence (Promega, Madison, WI) was T4 kinase 
end-labeled with 
32
P (Perkin Elmer, Waltham, MA) and was utilized for all studies.  
 Western blots 
 Twenty-four and forty-eight hours after treatment of PC-3 and DU145 cells with 0 or 5 M 
of DMAPT, or 0 or 4 M of DMAPT, respectively, cells were analyzed for changes in protein 
expression by our standard Western analysis (26, 28, 46). The primary antibodies utilized were 
anti-p53 (Ab-6, Calbiochem and clone BP53-12 Upstate), anti-p73 (rabbit polyclonal, 
Chemicon),  anti-p21
waf-1/Cip-1
 (clone 6B6, BD Pharmingen and mixed monoclonal, Upstate), 
anti-Bax (Clone YTH-2D2, Trevigen), anti-Bcl-2 (clone 124, Dako), anti-Bid (BD Pharmingen), 
and anti--tubulin (cloneB-5-1-2, Sigma).  The membranes were incubated with appropriate 
secondary antibodies conjugated with peroxidase (Pierce, Rockford, IL).  
 
Single fraction X-ray survival studies with and without DMAPT  
 All X-ray in vitro studies of PC-3 and DU145 cells were conducted using a 160 kV Faxitron 
X-ray Machine (Faxitron Bioptics, Tucson, AZ). Settings for the Faxitron X-ray machine were 
0.5 mm Cu filter, d=33 cm, and dose rate 62.8 cGy/min. X-ray dosimetry was performed 
according to the AAPM Task Group 61 protocol using a PTW N300001 ion chamber and an 
electrometer calibrated by the University of Wisconsin Accredited Dosimetry Calibration 
Laboratory (UW-ADCL) (47, 48).  PC-3 cells were treated with 0 and 5 M DMAPT. DU145 
cells were treated with 0 or 4 M of DMAPT. After incubation for 24 hours with DMAPT the 
PC-3 and DU145 cells were treated with a second dose of 5 or 4 M DMAPT, respectively, and 
then were irradiated with a single dose of between 0 and 6 Gy of 160 kVp X-rays. After an 
additional 24 h for repair, both PC-3 and DU145 cells were trypsinized; single cell suspensions 
were then prepared and counted. At each X-ray dose, appropriate numbers of cells were then 
plated into six T-25 flasks for standard colony forming assays by our published methods to 
assess clonogenic capacity/plating efficiency and survival (26, 28, 48, 49). As previously stated, 
the surviving fractions after various X-ray doses and DMAPT treatments were normalized for 
the toxicity of DMAPT alone. This was done to distinguish enhancement of radiation-induced 
cell killing from merely additive toxicity of the drug and radiation (26, 28). The Surviving 
Fraction (SF) mean ± SD of the radiation-alone versus the SF mean ± SD observed with DMAPT 
and radiation were compared by the Student’s t-test for significance (P ≤ 0.05).  Each experiment 
was performed a minimum of six times.  
 
Single fraction X-ray survival studies of cells pre-treated with NAC prior to DMAPT treatment  
 In order to better determine the mechanism of DMAPT-mediated radiosensitization, studies 
were performed in both the PC-3 and DU145 cells lines with pre-treatment of the cells with NAC 
prior to DMAPT treatment and radiation. PC-3 and DU145 cells in the NAC-pre-treatment group 
were treated with 20 mM NAC for 4 hours and were then  washed with PBS. Cells were then 
treated with DMAPT immediately and 24 hours later, irradiated with a single dose of between 0 
and 6 Gy of 160 kVp X-rays, and plated to assess clonogenic capacity/plating efficiency and 
survival in the aforementioned manner (26, 28, 48, 49). 
 
 
 
Immediate plating and split-dose repair experiments 
 A control group and five experimental groups were used for both PC-3 and DU145 cell 
immediate plating and split-dose repair experiments. The five experimental conditions were: 
DMAPT only (5 or 4 M, for PC-3 or DU145, respectively), 4 Gy with immediate plating, 4 Gy 
with DMAPT (5 or 4 M, for PC-3 or DU145, respectively) and immediate plating, and 2 x 2 Gy 
split-dose group with or without DMAPT treatment (5 or 4 M, for PC-3 or DU145, 
respectively). For both PC-3 and DU145 2 X 2 Gy split-dose groups a 4-hour incubation at 37°C 
was present between the two 2 Gy treatments to allow for repair. Cells were irradiated on ice to 
prevent repair during the treatments (26, 28).  
 
Comet assay 
 To investigate whether DMAPT altered the repair of X-ray-induced DNA double strand 
breaks (DSBs), neutral comet assays were performed using CometAssay
TM
 kits (Trevigen 4252-
040-K) employing our standard methodology (28). PC-3 and DU145 cells were treated with 0 
or 5 μM, or 0 or 4 μM DMAPT, respectively at 24 and 48 hours. After the second DMAPT 
treatment, cells were irradiated at 20 Gy of 160 kVp X-rays. To monitor DSB rejoining, cells 
were placed at 37ºC for 0 to 24-hour incubation periods and then at select times trypsinized, 
washed with PBS, embedded in agarose, lysed and subjected to neutral gel electrophoresis. 
Immediately before image analysis, cells were treated with SYBR green (Thermo Fisher 
Scientific). The cells were examined using a Leica CTR 5000 fluorescent microscope (Lecia 
Microsystems, Wetzlar, Germany) and comet images were captured using the SPOT RT
TM
 
software (SPOT Imaging Solutions, Sterling Heights, MI). The comet tail moments (50, 51) 
were analyzed by TriTekCometScore Freeware program (www.autocomet.com). Average tail 
moment values versus incubation times after 20 Gy of X-rays were calculated by measuring the 
tail moments of at least 100 cells per sample.  
 
Protocol for in vivo study in nude mice 
 In vivo PC-3 tumor xenograft studies were carried out with athymic nude mice (Envigo, 
Indianapolis, IN). In accordance with our standard procedure, mice were injected subcutaneously 
with between 5 and 10 million PC-3 cells in the right flank; tumors were then allowed to grow 
for seven days (28, 48). The PC-3 tumor xenografts were then randomly assigned to either the 
control or one of three treatment groups:  DMAPT only, 4 Gy only, or DMAPT plus 4 Gy. 
Beginning on day 8 post-subcutaneous injection, the mice in the control group were given 2.5% 
mannitol by oral gavage, while the DMAPT-treated groups were given 100 mg/kg DMAPT in 
2.5% mannitol daily for 7 days. The tumor xenografts in the irradiated groups were irradiated 
with a single fraction of 4 Gy with a 320 Precision X-ray Machine (Precision X-ray, North 
Bradford, CT) using a collimated 2.0 x 2.0 cm field size that focused the radiation treatment on 
the tumor and minimized the amount of normal tissue irradiated. The mice in the DMAPT with 4 
Gy treatment group received the 4 Gy dose of X-rays on the third day after the DMAPT 
treatment began. Settings for the Precision X-ray machine were 250 kVp, 2.0 mm Cu/Th filter, 
d= 50 cm, and dose rate 1.59 Gy/min.  All animal experiments were conducted under an 
approved Indiana University School of Medicine IUACUC protocol in our fully ALAC 
accredited IUSOM animal facility. 
 
Statistical analyses 
 The Surviving Fraction (SF) means ± SD of the radiation-alone versus the SF means ± SD 
observed with DMAPT and radiation for the above single fraction and split-dose clonogenic 
survival experiments were compared by the Student’s t-test for significance (P ≤ 0.05).  The 
Comet Tail Moments (50, 51) means for each time point for radiation-alone versus radiation and 
DMAPT were compared by the Student’s t-test for significance (P ≤ 0.05).  Each in vitro 
experiment was performed four to six times. For the PC-3 tumor xenograft studies, tumor 
volume was measured in each xenograft on day 8 post-injection. Tumor volume was 
subsequently measured at intervals of 2-4 days up until day 59 post-injection. Using the 
originally measured tumor volume on day 8 post-injection, the relative tumor volume was 
determined on each day of measurement for each of the xenografts. This data was compiled to 
determine the average relative tumor volume for each of the four groups on each day of 
measurement. The average relative tumor volume in each group was then used to create a tumor 
growth curve and a one-way ANOVA was performed to determine the statistical significance of 
the relative tumor volume on each day of measurement.  
 
Results 
DMAPT decreases constitutive NF-B binding activity, inhibits cell proliferation and viability of 
PC-3 and DU145 cells 
 Electrophoretic Mobility Shift Assays (EMSA) were performed to investigate whether 
treatment of PC-3 or DU145 prostate cancer cells with DMAPT altered the binding affinity of 
the p65/p50 heterodimer of NF-B to its DNA promoter consensus sequence in either cell type.  
Treatment of PC-3 and DU145 cells with 5 and 4 M DMAPT, respectively, for 48 hours 
reduced binding activity of the NF-B p65/p50 heterodimer transcription factors in both cell 
lines (Figs. 1A & 1B, left panels). In addition, treatment of PC-3 and DU145 cells with 5 and 4 
M DMAPT, respectively, increased the population doubling times of PC-3 prostate cancer cells 
from 23.0 ± 5.0 hours to 42.0 ± 3.0 hours and of the DU145 cells from 20.4 ± 2.2 hours to 72.5 ± 
24.8 hours (Figs. 1A & 1B, right upper panels) (P < 0.05). Clonogenic survivals were performed 
to establish plating efficiencies and determine if the increased doubling times in PC-3 and 
DU145 cells could in part be due to induction of cell death by DMAPT. Treatment with DMAPT 
for 48 hours significantly decreased the clonogenic plating efficiency of PC-3 cells from 0.31 ± 
0.07 to 0.14 ± 0.05 (P < 0.05) and reduced the clonogenic plating efficiency of DU145 cells from 
0.45 ± .08 to 0.22 ± 0.07 (P < 0.05), indicating that cell death does appear to play a role in the 
observed increase in cell population doubling time following treatment with DMAPT (Figs. 1A 
& 1B, right lower panels). However, analysis of whether the DMAPT treated cells are dying by 
apoptosis by Annexin V flow cytometry indicates no significant difference in the percentage of 
cell undergoing apoptosis in either PC-3 or DU145 cells that were treated with DMAPT versus 
the untreated control cells (Figs. 2A & 2B, left panels).  Moreover, Western blots show no 
obvious evidence of induction of pro-apoptotic or anti-apoptotic BCL proteins such as Bax, Bcl-
2, or Bid (Figs. 2A & 2B, right panels). These data indicate that the increased cell death observed 
after the treatment of PC-3 and DU145 cells with DMAPT cannot be explained by the induction 
of apoptosis. 
 
DMAPT reduces radiation-induced NF-B binding activity and increases radiation-induced cell 
killing of PC-3 and DU145 cells 
 The binding activity of the p65/p50 heterodimer of NF-B to its consensus promoter 
sequence has been shown by us and other investigators to be X-ray-inducible and associated with 
radiation resistance (10, 11, 17).  We therefore performed NF-B EMSA gel shift studies to 
investigate whether treatment of PC-3 or DU145 cells with DMAPT altered the kinetics or 
intensity of radiation-induced NF-B activation in PC-3 and DU145 cells.  PC-3 and DU145 
cells were irradiated with 6 Gy and nuclear extracts were obtained from irradiated cultures of 
PC-3 and DU145 cells treated with and without DMAPT at 0, 15, 30, 45, and 60 minutes post-
irradiation. Radiation-induced NF-B binding activity in PC-3 cells was elevated from 15 to 45 
minutes after 6 Gy, and treatment with DMAPT completely inhibited radiation-induced NF-B 
binding activity in PC-3 cells (Fig. 3A). Radiation-induced NF-B binding activity in DU145 
cells was elevated from 30 to 60 minutes after 6 Gy, and treatment with DMAPT reduced but did 
not completely suppress radiation-induced NF-B binding activity in DU145 cells (Fig. 3B).  
 To test whether treatment of PC-3 or DU145 cells with DMAPT would alter radiation-
induced cell killing, PC-3 and DU145 cells were treated for 48 hours with or without DMAPT, 
irradiated with a single dose of X–rays in the range of 0 to 7 Gy, incubated for another 24 hours 
with or without DMAPT, and then plated for colony formation. DMAPT treatment increased X-
ray-induced cell killing compared to irradiated controls at 2, 4, and 6 Gy in PC-3 cells and at 3, 
4, 5, 6, and 7 Gy in DU145 cells (Fig. 4, upper panel) (P < 0.05). It should be noted that the 
calculated cell survivals of the DMAPT-treated PC-3 and DU145 cells have been corrected for 
drug-related toxicity and therefore toxicity related to DMAPT cannot account for the enhanced 
X-ray-induced cell killing that was observed.   
Treatment with NAC reduces DMAPT-induced radiosensitization of PC-3 and DU145 cells 
 To test whether pre-treatment with NAC reduced the enhanced radiation-induced cell killing 
seen in cells treated with DMAPT,  PC-3 and DU145 cells were treated with NAC for 4 hours 
prior to washing and then treating the cells with DMAPT immediately and 24 hours later and 
then irradiating them. In both the PC-3 and DU145 cell lines pre-treatment with NAC 
significantly reduced, but did not eliminate, the enhanced radiation-induced cell killing of cells 
treated with DMAPT and 6 Gy of X-rays (Fig. 4, lower panel) (P < 0.05). 
 
DMAPT alters cell cycle distribution 
 Flow cytometry was then performed to investigate whether altered cell cycle distribution out 
of the radiation resistant S phase or into the radiation sensitive G2/M phase could explain the 
DMAPT-induced radiosensitization of p53 null PC-3 or DU145 prostate cancer cells. Flow 
cytometry indicated that while DMAPT treatment of PC-3 cells did increase the number of cells 
in the radiation sensitive G2/M phase from 18% to 27%, it also increased the number of radiation 
resistant S phase cells increasing from 38% to 54% (Fig. 5A).  As previously mentioned, 
Western blot analysis confirmed that PC-3 was p53 null and showed that DMAPT did not induce 
p21
waf1/cip1
, a powerful inhibitor of the cell cycle progression at multiple cell cycle check points 
(Fig. 2). Therefore, the observed changes in the cell cycle induced by DMAPT treatment appear 
not to be a function of p53 activation and subsequent up-regulation of p21
waf1/cip1
. By contrast, 
flow cytometric assessment of alterations of cell cycle in DMAPT treated DU145 cells did not 
show an increase in the percentage of radiation-sensitive cells in G2/M phase, but it too showed 
an increase in the number of radiation-resistant cells in S phase from 30% to 55% (Fig. 5B).  
Taken together the data suggest that the observed increase in X-ray sensitivity of PC-3 and 
DU145 cells after treatment with DMAPT cannot be explained by redistribution of the cells into 
radiation sensitive phases of the cell cycle.   
    
DMAPT  inhibits split-dose repair and enhances fractionated x-ray-induced cell killing  
 X-ray fractionation studies were performed to investigate whether DMAPT increased 
radiation-induced killing of PC-3 and DU145 cells through inhibition of split-dose repair. The 
surviving fraction of PC-3 cells that were treated with 0 or 5 M DMAPT or DU145 cells treated 
with 0 or 4 M DMAPT were then given either a single fraction of 4 Gy of X-rays or two 
fractions of 2 Gy of X-rays 2 hours apart to allow for repair. The data show that the survival 
fractions of both PC-3 and DU145 cells treated with DMAPT and 2 Gy + 2 Gy fractionated 
radiation were significantly lower than the surviving fractions of PC-3 and DU145 cells that 
were treated with 2 Gy + 2 Gy  fractionated radiation alone (Fig. 6A) (P < 0.01).  
 
DMAPT inhibits DNA double-strand break repair in irradiated PC-3 and DU145 prostate 
cancer cells 
 To directly investigate whether the above inhibition of split dose repair by DMAPT treatment 
was due to inhibition of DNA double-strand break repair, flasks of PC-3 (left) and DU145 (right) 
cells were irradiated with 20 Gy of X-rays on ice with and without treatment with DMAPT and 
samples at various time points post-irradiation were prepared for neutral comet assay, which 
assesses both radiation-induced DNA double-strand break (DSB) induction and repair (50-52). 
The mean ± s.d. Comet olive tail moments for 50 individual cells from each treatment group of 
PC-3 and DU145 cells were determined and plotted versus time post-irradiation (6B, lower 
panels). The 20 Gy control comet data for both PC-3 and DU145 clearly show evidence of the 
classic fast and slow bimodal repair kinetics versus time post-irradiation that has been reported 
by us and other investigators (50, 51, 53, 54). The data also show that treatment with DMAPT 
results in significantly longer tail moments (i.e. less DSB repair) in irradiated PC-3 cells at 1, 3, 
and 6 hours post-irradiation and in irradiated DU145 cells at 3, 6, and 14 hours post-irradiation 
compared to the results from 20 Gy irradiated control PC-3 and DU145 cells (Fig. 6B, lower 
panels) (P < 0.05). The data indicate that treatment with DMAPT alters the fast and slow 
components of DNA DSB repair post-irradiation in both PC-3 and DU145 cells.  We and others 
have shown that altered radiation-induced DSB repair kinetics post-irradiation is strongly 
correlated with increased radiation-induced cell death in mammalian cells (50, 51, 53, 54). 
 
Treatment with DMAPT increases sensitivity of PC-3 tumor xenografts to X-rays 
 PC-3 tumor xenograft studies were performed to determine whether DMAPT increases 
sensitivity of PC-3 cells to X-rays in vivo. Treatment of xenografts with the combination of 
DMAPT and 6 Gy of X-rays resulted in significantly lower average relative tumor volumes on 
day 59-post-implantation compared to xenografts that were untreated or treated with either 
DMAPT or 6 Gy of X-rays alone (Fig. 7) (P < 0.05). 
 
 
Discussion 
 Previous work in our laboratory has shown that parthenolide, a naturally occurring 
sesquiterpene lactone, is a potent radiosensitizing agent that is effective at increasing the 
sensitivity of the human prostate adenocarcinoma cell line PC-3 to X-rays in vitro (26, 27). 
However, given its poor bioavailability, the clinical utility of parthenolide as a radiosensitizing 
agent is limited (33). Thus, we investigated whether DMAPT, a derivative of parthenolide with 
increased bioavailability, would be able to increase the sensitivity of not only PC-3 (p53 null) but 
also DU145 (p53 mutant) prostate cancer cells to X-rays in vitro and in vivo (28, 35-38). 
 Treatment of PC-3 cells with 5 M DMAPT at 24 and 48 hours reduced constitutive NF-B 
activation (Fig. 1A, left panel), inhibited cell growth, and reduced plating efficiency (Fig. 1A, 
right lower panel).  The increased cell population doubling time observed in PC-3 cells that were 
treated with DMAPT (Fig. 1A, right upper panel) is consistent with the growth inhibition seen in 
this cell line when treated with parthenolide (26, 27). While the increase in doubling time 
observed following treatment with DMAPT might be explained by an increase in cell death, 
Annexin V flow cytometry assays showed that DMAPT treatment did not increase apoptosis in 
PC-3 cells (Fig. 2A, left panel). Moreover, Western blot results showed that DMAPT did not 
change the expression of pro- or anti-apoptotic proteins (Fig 2A, right panel). Taken together, 
these results suggest that apoptosis is not responsible for the increased cell killing seen in 
DMAPT-treated PC-3 cells. These studies were also performed using DU145 prostate 
adenocarcinoma cells, which similarly showed reduced constitutive NF-B activation, increased 
doubling time, and reduced plating efficiency that could not be explained by apoptosis following 
treatment with DMAPT (Figs. 1B and 2B). 
 PC-3 cells have been found to express NF-B constitutively and in response to ionizing 
radiation (7). Thus, we investigated whether DMAPT would decrease radiation-induced NF-B 
binding in PC-3 cells. We found that treatment of PC-3 cells with DMAPT completely inhibited 
radiation-induced NF-B binding in this cell line (Fig. 3A). While this effect was not as 
pronounced in the DU145 cell line (Fig. 3B), DMAPT increased X-ray-induced cell killing in 
both PC-3 and DU145 cell lines (Fig. 4, upper panel). 
 As previously mentioned, parthenolide is known to be a potent thiol alkylating agent and is 
known to exert an anti-neoplastic effect via this mechanism. However, given that the α-
methylene-γ-lactone group of parthenolide has been modified in DMAPT in order to increase the 
drug’s bioavailability, it is relatively unknown whether the aforementioned DMAPT-induced 
radiosensitization is mediated via the alteration of intracellular thiol reduction-oxidation 
chemistry (32, 40). As such, we performed experiments to test whether pre-treatment with the 
thiol antioxidant NAC would inhibit the ability of DMAPT to radiosensitive PC-3 and DU145 
cells. Our results showed that while pre-treatment with NAC significantly decreased the degree 
of radiosensitization seen in both cell lines following treatment with DMAPT, it did not 
completely eliminate this effect. Thus, this novel finding provides evidence that although some 
of the DMAPT-induced radiosensitization seen in these cell lines is due to alterations in 
intracellular thiol reduction-oxidation chemistry, these alterations alone are not sufficient to 
explain the mechanism of DMAPT-induced radiosensitization.  
 In an additional attempt to  explain the radiosensitization seen in PC-3 and DU145 cells 
following treatment with DMAPT, cell cycle analysis was utilized. We found that while 
treatment with DMAPT resulted in a small increase in the number of PC-3 cells in the 
radiosensitive G2/M phase, it also resulted in an even larger increase in the number of cells in the 
radioresistant S phase (Fig. 5A). Similarly, we found that DMAPT had no effect on the number 
of DU145 cells in the radiosensitive G2/M phase and resulted in a significant increase in the 
number of cells in the radioresistant S phase. Thus, our results indicate that DMAPT-induced 
radiosensitization does not occur because of cell cycle changes in either of these cell lines. 
 In a further effort to understand DMAPT’s role as a radiosensitizing agent, we also 
performed split-dose experiments in which DMAPT-treated and untreated cells were irradiated 
with 4 Gy of X-rays, either in a single fraction or in two fractions of 2 Gy. We found that the 
surviving fraction of PC-3 cells that were treated with DMAPT combined with two fractions of 2 
Gy of X-rays was significantly lower than the surviving fraction of PC-3 cells that were treated 
with DMAPT combined with a single fraction of 4 Gy of X-rays, or with radiation alone (Fig. 
6A, left panel). Although these results could not be replicated in DU145 cells (Fig. 6A, right 
panel), our results in the PC-3 cell line suggest that treatment with DMAPT might decrease cell 
survival by impairing the ability of these cells to repair radiation-induced double strand DNA 
breaks. This idea is supported by the results of the comet assays, in which significantly larger tail 
moments, created by double stranded DNA fragments, were detected in PC-3 cells that were 
treated with a combination of DMAPT and radiation compared with those that were treated with 
radiation alone (Fig. 6B). overall, these data support the idea that DMAPT-mediated inhibition of 
radiation-induced NF-B expression inhibits DNA double strand break repair, and is at least 
partially responsible for the effectiveness of DMAPT as a radiosensitizing agent in PC-3 prostate 
adenocarcinoma cells, further studies to identify the molecular mechanisms involved are 
underway.  
 Finally, we have demonstrated that DMAPT is effective as a radiosensitizing agent in vivo in 
a nude mouse model. PC-3 tumor xenografts that were treated with oral DMAPT at 100 mg/kg 
daily for 7 days combined with 6 Gy of X-rays had significantly smaller tumor volumes 
compared to xenografts that were untreated, or treated with either DMAPT or radiation alone 
(Fig. 7). Very recent work by Morel et al showed that DMAPT is able to radiosensitize prostate 
cancer cells in vivo in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model (39). 
This work provides further support for our conclusion that DMAPT is able to radiosensitize 
prostate cancer cells in vivo. Moreover, the finding by Morel et al that DMAPT also acts as a 
radioprotecting agent in normal tissues in vivo increases the future potential for DMAPT as a 
therapeutic and radiosensitizing agent for prostate cancer (39). 
 Although current therapeutic regimens offer a favorable prognosis for many older men with 
prostate cancer, the disease remains the second most common cause of cancer death in men, 
primarily as a result of the poor prognosis the disease portends in younger men, and African 
American men (1-7). To improve the prognosis of prostate cancer in these populations new 
therapeutic paradigms are necessary. Based upon our findings herein, we believe that DMAPT 
has the potential to be used clinically as a radiosensitizing agent in the treatment of prostate 
cancer. Moreover, further investigations should be undertaken to evaluate DMAPT as a 
radiosensitizing agent in other malignancies where NF-B is activated, as our lab has done 
previously with non-small cell lung cancer (28). 
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Figure 1 EMSA gel shift assays showing NF-B p65/p50 heterodimer transcription factor 
binding to consensus promoter sequence in PC-3 cells (A, left panel) and DU145 cells (B, left 
panel) with and without treatment with DMAPT. Population doubling times of PC-3 cells (A, 
middle panel) and DU145 (B, middle panel) with and without treatment with DMAPT. Plating 
efficiency of PC-3 cells (A, right panel) and DU145 cells (B, right panel) with and without 
treatment with DMAPT. *P < 0.05, Student’s t test.  
 
Figure 2 (A and B, left panels) Annexin V flow cytometry results showing percentage DMAPT-
treated and untreated control PC-3 (A) and DU145 (B) cells undergoing apoptosis. (A and B, 
right panels) Western blots for pro-apoptotic and anti-apoptotic proteins in DMAPT-treated and 
untreated control PC-3 (A) and DU145 (B) cells. 
 
Figure 3 (A and B, left panels) EMSA showing NF-B p65/p50 heterodimer transcription factor 
binding to consensus promoter sequence in untreated PC-3 (A) and DU145 (B) cells following 
treatment with 6 Gy of X-rays. (A and B, right panels) EMSA showing NF-B p65/p50 
heterodimer transcription factor binding to consensus promoter sequence in DMAPT-treated PC-
3 (A) and DU145 (B) cells following treatment with 6 Gy of 160 kVp X-rays. 
 
Figure 4 (Left, upper panel) Surviving fraction of PC-3 cells with and without treatment with 
DMAPT prior to receiving a single dose of either 0, 2, 4, or 6 Gy of X-rays. *P < 0.05, Student’s 
t test. (Right, upper panel) Surviving fraction of DU145 cells with and without treatment with 
DMAPT prior to receiving a single dose of  0, 3, 4, 5, 6 or 7 Gy of 160 kVp X-rays. *P < 0.05, 
Student’s t test. (Left, lower panel) Surviving fraction of PC-3 cells pre-treated or untreated with 
NAC with and without treatment with DMAPT prior to receiving a single dose of either 0, 2, 4, 
or 6 Gy of X-rays. *P < 0.05, Student’s t test. (Right, lower panel) Surviving fraction of PC-3 
cells pre-treated or untreated with NAC with and without treatment with DMAPT prior to 
receiving a single dose of either 0, 2, 4, or 6 Gy of X-rays. *P < 0.05, Student’s t test.    
 
Figure 5 DNA flow cytometry analysis after propidium iodide (PI) staining to determine the cell 
cycle distribution or percentage of cells in G1, S, and G2/M phase of PC-3 (A) and DU145 (B) 
cells that were treated with DMAPT versus cells untreated controls. No radiobiologically 
significant changes in cell cycle distribution were observed after treatment with DMAPT 
compared to controls. 
 
Figure 6 (A, upper  panels) Fractionation studies were performed to determine the surviving 
fraction of DMAPT-treated and untreated PC-3 (left) and DU145 (right) cells following 
treatment with 4 Gy of 160 kVp X-rays, either as a single fraction or as two fractions of 2 Gy, *P 
< 0.01, Student’s t test. (B, lower panels) PC-3 (left) and DU145 (right) cells were irradiated 
with 20 Gy of X-rays on ice with and without treatment with DMAPT and at various time post-
irradiation were prepared for neutral comet assay. The comet olive tail moment for 50 individual 
cells from each treatment group are shown, *P < 0.05, Student’s t test. 
 
Figure 7 Average relative tumor volume of PC-3 tumor xenografts following treatment with 6 
Gy of X-rays and/or DMAPT. Athymic nude mice were injected with PC-3 cells on day 0 of the 
experiment. Xenografts in groups that received DMAPT were given 100 mg/kg DMAPT daily 
on days 8-14 post-implantation. Xenografts in groups that received radiation were irradiated with 
a 2 x 2 cm field of 6 Gy of 250 kVp X-rays on day 11 post-implantation. *P < 0.05, one-way 
ANOVA. 
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Highlights 
 DMAPT inhibited constitutive and radiation-induced NF-B binding activity. 
 DMAPT slowed cell growth. 
 DMAPT significantly increased single and fractionated X-ray induced cell killing in 
vitro. 
 DMAPT inhibited X-ray induced DNA double strand break (DSB) repair in vitro. 
 DMAPT enhanced X-ray induced anti-tumor activity in vivo. 
 
 
